Business
Mineralys Therapeutics Announces Presentation of New Data from the Phase 3 Launch-HTN Trial of Lorundrostat at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)
– Oral presentation highlights efficacy and safety profile of lorundrostat in patients with uncontrolled hypertension and chronic kidney disease – RADNOR, Pa., May 18, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced that new data
About this update from Mineralys Therapeutics, Inc.
[{"type":"image","alt":"Mineralys Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Mineralys Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":79,"url":"https://media.zenfs.com/en/globenewswire.com/7d27eb215a09ca1c260f3840d5c29c6c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/oMsxZW8ttKTHAHjG2pEt6g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExMQ--/https://media.zenfs.com/en/globenewswire.com/7d27eb215a09ca1c260f3840d5c29c6c","width":300,"height":79},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/oMsxZW8ttKTHAHjG2pEt6g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExMQ--/https://media.zenfs.com/en/globenewswire.com/7d27eb215a09ca1c260f3840d5c29c6c","width":300,"height":79}},"lazy":false},{"type":"text","content":"– Oral presentation highlights efficacy and safety profile of lorundrostat in patients with uncontrolled hypertension and chronic kidney disease –","length":146,"tagName":"p"},{"type":"text","content":"RADNOR, Pa., May 18, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced that new data from its Phase 3 Launch-HTN trial in participants with hypertension and CKD will be featured in an oral presentation at the 35th European Meeting on Hypertension and Cardiovascular Protection (ESH 2026), taking place May 28–31, 2026 in Gdańsk, Poland.","length":604,"tagName":"p"},{"type":"text","content":"Details for the Oral Presentation:","length":34,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"style":"max-width:18%;width:18%;min-width:18%;border-top:solid black 1pt;border-right:solid black 1pt;border-bottom:solid black 1pt;border-left:solid black 1pt;vertical-align:middle;text-align:left;padding-left:10.0px;vertical-align:top;","val":[{"type":"text","content":"Abstract Title:","length":15,"tagName":"p","attribs":{}}]},{"style":"max-width:82%;width:82%;min-width:82%;border-top:solid black 1pt;border-right:solid black 1pt;border-bottom:solid black 1pt;border-left:solid black 1pt;vertical-align:middle;text-align:left;padding-left:10.0px;vertical-align:top;","val":[{"type":"text","content":"Lorundrostat for Hypertens...